Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) announced it will present interim results from its Phase 1 healthy volunteer trial of SPY001, a novel half-life extended anti-α4β7 antibody designed to treat Inflammatory Bowel Disease (IBD). The company will host a conference call and webcast on November 12, 2024, at 8:00am ET to discuss the findings. The webcast will be accessible through Spyre's Investor Relations webpage and will be archived for -time viewing.

WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced it will report interim results from the Phase 1 SPY001 healthy volunteer trial on Tuesday, November 12, 2024. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results.

To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-presentations. The archived webcast will be available for a limited time on the Company's website.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com. 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-from-phase-1-healthy-volunteer-trial-for-spy001-its-novel-half-life-extended-anti-47-antibody-for-the-treatment-for-inflammatory-bowel-disease-on--302301674.html

SOURCE Spyre Therapeutics, Inc.

FAQ

When will Spyre Therapeutics (SYRE) report Phase 1 interim results for SPY001?

Spyre Therapeutics will report interim results from the Phase 1 SPY001 healthy volunteer trial on November 12, 2024, followed by a conference call and webcast at 8:00am ET.

What is SPY001 being developed for by Spyre Therapeutics (SYRE)?

SPY001 is a novel half-life extended anti-α4β7 antibody being developed by Spyre Therapeutics for the treatment of Inflammatory Bowel Disease (IBD).

How can investors access Spyre Therapeutics' (SYRE) November 12 webcast?

Investors can access the live and archived webcast through Spyre's Investor Relations website at https://ir.spyre.com/events-and-presentations.